临床研究
更频繁的诊所访问与非酒精性脂肪肝与儿童的改善结果
|
|
集团 |
基线 |
结果 |
价值 |
|
| ALT (U / L) |
NAFLD3M |
100 (90) |
75 (54) |
0.02 |
| HEP1Y |
101 (81) |
85 (70) |
0.09 |
| AST (U / L) |
NAFLD3M |
57 (43) |
44 (27) |
0.03 |
| HEP1Y |
60 (35) |
52 (40) |
0.11 |
| GGT (U / L) |
NAFLD3M |
41 (30) |
31 (18) |
< 0.01 |
| HEP1Y |
63 (53) |
57 (48) |
0.07 |
| 高山(U / L) |
NAFLD3M |
247 (107) |
206 (89) |
< 0.01 |
| HEP1Y |
238 (95) |
212 (96) |
0.05 |
| 低密度脂蛋白(更易/ L) |
NAFLD3M |
2.5 (0.6) |
2.5 (0.6) |
0.38 |
| HEP1Y |
2.9 (0.1) |
2.7 (0.3) |
0.19 |
| 高密度脂蛋白(更易/ L) |
NAFLD3M |
1.2 (0.3) |
1.1 (0.3) |
0.36 |
| HEP1Y |
0.9 (0.1) |
0.9 (0.1) |
0.25 |
| 总胆固醇(更易/ L) |
NAFLD3M |
4.4 (0.8) |
4.3 (0.7) |
0.19 |
| HEP1Y |
5.2 (1.1) |
5.0 (1.3) |
0.53 |
| 甘油三酸酯(更易/ L) |
NAFLD3M |
1.3 (0.8) |
1.4 (1.0) |
0.56 |
| HEP1Y |
2.1 (1.3) |
1.7 (1.0) |
0.37 |
| PLT (×109/ L) |
NAFLD3M |
288 (49) |
290 (62) |
0.88 |
| HEP1Y |
326 (55) |
316 (56) |
0.33 |
|
|
数据表示为手段(SD)。
|